Following a record-breaking year for IPOs and other going-public transactions in 2021, the beginning of 2022 has presented a challenging environment. That’s largely a result of volatile market conditions due to the ongoing...more
Public market investors have offered a warm welcome to life sciences companies so far in 2021. As Fenwick’s recent H1 2021 Going Public Report shows, the pace has picked up as 2021 progresses, with 31 life sciences IPOs in...more
The life sciences sector will likely be one of the major drivers in what some analysts predict as the beginning of the largest economic expansion in recent history. ...more
3/25/2021
/ Coronavirus/COVID-19 ,
Digital Health ,
Infectious Diseases ,
Initial Public Offering (IPO) ,
Innovative Technology ,
Investment Opportunities ,
Life Sciences ,
Pharmaceutical Industry ,
Special Purpose Acquisition Companies (SPACs) ,
Startups ,
Vaccinations ,
Venture Capital